Swiss researchers have developed a method that combines bacterial
capture, lysis and the purification of plasmid DNA to improve
industrial-scale bioprocesses.
Despite numerous media reports of an impending patent infringement
suit, Sanofi-Aventis has yet to formally hear anything from
plaintiff Novo Nordisk, who claims the French firm's SoloStar
insulin pen violates patents covering...
Australian drug delivery specialist Acrux has reported positive
results in Phase II trials of its innovative under-arm lotion
formulation for testosterone replacement therapy.
At a packed out session at last week's Controlled Release Society
meeting in the US, two experts battled it out to win one of the key
debates in gene delivery: which is superior - viral or non-viral
delivery?
Integrated DNA Technologies (IDT) has launched a new kit for
cloning libraries of small RNAs from any primary RNA source to
enable the discovery of new small RNA molecules.
Computer giant IBM has re-inked a huge $1.4bn (€1.0bn) IT
outsourcing deal with drug giant AstraZeneca, who is continuing its
cost-cutting drive to become 'lean and agile'.
Research being carried out at the University of Utrecht in the
Netherlands to replace standard vaccination schedules with a
single-shot alternative could do away with the need for repeated
jabs.
Biopol Laboratory is acting to meet the demand of sneezes, itchy
eyes and running noses as it consolidates its five allergen
production facilities into one main building in Idaho.
US biopharmaceutical company VGX has strengthened its position in
the plasmid DNA area with the award of two new patents covering the
use and manufacture of plasmid DNA.
UK-based deltaDOT has been given a key role providing analytical
technologies to a consortium aiming to increase the efficiency of
vaccine and biological drug production.
A drug developed from the milk of transgenic animals is one step
closer to being the second such drug on the market following a
European thumbs up of its facilities, marking a significant move in
the controversial drug development...
A new needle-free delivery system is taking a stab at the
traditional needle and syringe after winning an award at the 2007
Medical Futures Innovation Awards.
An Israeli drug delivery firm is developing a new vaginal drug
delivery system, making use of bio-adhesive foams to offer a more
convenient and effective treatment option for women with
gynaecological complaints.
A novel technology set to overcome the challenges of the blood
brain barrier is being developed in a bid to open the gates to
previously unusable compounds for the treatment of central nervous
system (CNS) disorders.
Immune Targeting Systems (ITS) has received £4m (€5.9m) to aid in
its development of synthetic peptide vaccines for mutating viruses
such as influenza, HIV and Hepatitis C.
University of Texas at Arlington (UTA) spin-out has exclusively
licensed plasma coating technology that could improve the
controlled release of drugs and the biocompatibility of medical
implants.
Parexel talks to Outsourcing-Pharma about its clinical research
experiences in emerging hot spot Latin America, as the contract
research organisation (CRO) has a presence in every country in this
continent that conducts international...
LabTechnologist.com brings you an exclusive interview with Ger
Brophy - general manager of Advanced Systems within GE Healthcare's
Life Science Division.
As Outsourcing-Pharma.com continues to investigate the
circumstances of the Inyx group's insolvency problems, it can
be revealed that some of the senior management have been
involved at a senior level in other firms that have...
LabTechnologist.com brings you its periodic round up of new product
releases, with new offerings from Activotec, Luminex, Nonlinear
Dynamics, Oxford Gene Technology, SP Industries, TandD, Thermo
Fisher Scientific and VWR.
US researchers have developed a microfluidic device for purifying
and concentrating DNA directly from blood samples that could speed
up the use of genomics in clinical trials.
Sigma-Aldrich is to collaborate with Sangamo BioSciences to develop
zinc finger DNA-binding proteins to create knock-out cell lines and
cell lines with enhanced protein production performance.
Covance is again at the centre of controversy as opponents of the contract research organisation (CRO) filed a lawsuit against a city in Arizona, aimed at stopping the firm from building a new drug-testing facility there.
A new generation of therapeutic protein products has entered the
biopharma scene and are proving more efficient than antibodies when
using the same drug delivery systems.
A new fluorescent chemical sensor can detect citric acid at low
concentrations more rapidly and cheaply than current optical
sensors, its developer claims.
Almost the entire international operations of specialty pharma
contract manufacturer Inyx is facing insolvency and the company is
locked in a legal battle with its principal financier.
Indian pharmaceutical manufacturing company Shasun Chemicals and
Drugs has now got its eye fully on the US market after recent
approval of its new formulation facility in Puducherry.
Transdermal drug delivery expert Noven Pharmaceuticals is to buy
JDS Pharmaceuticals in a deal worth $125m (€91m) to transform
itself into a 'fully-integrated speciality pharmaceutical company'.
Quintiles is planning to spend $19m ($14m) to consolidate its US
central lab and its clinical services office in
Georgia to one location and expand capacity at the same
time.
AstraZeneca (AZ) and Roche have became the latest big pharma firms
to invest in RNA interference (RNAi), having penned separate
licensing deals with two of the industry's leading specialists in
the field.
Indian contract manufacturing organisation (CMO) Dishman
Pharmaceuticals has announced its plans to buy Solvay
Pharmaceuticals' fine chemicals and vitamin businesses for an
undisclosed sum.
A UK biopharma firm's lead drug candidate has now shown good
preclinical results for rheumatoid arthritis, adding to its
clinical efficacy in Alzheimer's.
The world's number two manufacturer of rubber components for
pharmaceutical products, Helvoet Pharma, has broken ground on a new
facility that promises to double or even triple its capacity to
supply the fast-growing markets...
UK-based NanoBioDesign has received further investment to aid in
its commercialisation of a tool for testing drugs on P450 liver
enzymes, which could dramatically speed up drug toxicity testing.
In a refreshingly honest interview with a Danish newspaper, the
Lundbeck CEO has admitted his company is in crisis and needs to
restock its pipeline to avoid making it any worse.
Abraxis BioScience will be separating the company into two
independent public companies following accelerated growth, the
US-based firm announced this week.
A UK firm has introduced a new piece of kit for pharma firms to
test how the contents of their hard gel capsules can affect the
strength and stability of the outer shell.
German packaging firm Gerresheimer has been awarded another prize
for its innovative safety-conscious rigid needle shield, this time
winning the World Packaging Organisation's renowned WorldStar
award.
AstraZeneca is planning to gradually withdraw from making its own
active pharmaceutical ingredients (APIs) and will use China as the
pinnacle of its new outsourcing plans.
